Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE trial of reduced chemotherapy cycles with pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
2024-514875-16-00Phase 2Authorised
- Sponsor
- Institut Claudius Regaud
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, fluorouracil, carboplatin and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Institut Claudius Regaud. Primary endpoints: Objective response rate and Rate of patients with adverse events leading to any treatment discontinuation. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-514875-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514875-16-00.